Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Danaos Corporation (DAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Danaos Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.08 (market cap $39.89B), while Danaos Corporation trades at $130.99 (market cap $2.34B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 17× Danaos Corporation's market cap, and Danaos Corporation pays a 2.8% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DAC | |
|---|---|---|
Market Cap | $39.89B | $2.34B |
Sector | Health | Technology |
52-Week High | $491.22 | $134.63 |
52-Week Low | $278.09 | $84.05 |
Enterprise Value | $38.15B | $2.34B |
Dividend Yield | — | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DAC trades at $128.39, up 0.83% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 4.53, P/B of 0.6, and net income margin of 49.85%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company maintains a $0.90 quarterly dividend. Cash flow from operations remains robust at $645 million for 2025.
Outlook is positive given deep value metrics and high profitability, but risks include cyclical shipping demand and earnings volatility. Analyst consensus is mixed with 40% buy ratings. The stock offers value but requires monitoring of charter rate trends and global trade conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
